Association in molecular profiles of IgE sensitization to mugwort pollen allergens in Chinese parents and their offspring

Lan Zhao; Jiongyi Chen; Yuqi Wang; Yirong Guo; Yan Feng; Xuefeng Wang; Meiling Liu; Xueyan Wang; Tingting Ma; Huanping Zhang; Xiaoxue Chen; Xianqi Zhang; Wanyi Fu; Yi Liu; Puyang Xu; Biyuan Gao; Deyun Wang; Jaap H. Akkerdaas; Ronald van Ree; Rudolf Valenta; Susanne Vrtala; Zhongshan Gao

doi:10.1111/pai.14005

Association in molecular profiles of IgE sensitization to mugwort pollen allergens in Chinese parents and their offspring

Lan Zhao
, Jiongyi Chen
, Yuqi Wang
, Yirong Guo
, Yan Feng
, Xuefeng Wang
, Meiling Liu
, Xueyan Wang^*
, Tingting Ma
, Huanping Zhang
, Xiaoxue Chen
, Xianqi Zhang
, Wanyi Fu
, Yi Liu
, Puyang Xu
, Biyuan Gao
, Deyun Wang
, Jaap H. Akkerdaas
, Ronald van Ree
, Rudolf Valenta

Susanne Vrtala, Zhongshan Gao^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic

14 Downloads (Pure)

Original language	English
Article number	e14005
Journal	Pediatric allergy and immunology
Volume	34
Issue number	8
DOIs	https://doi.org/10.1111/pai.14005
Publication status	Published - 1 Aug 2023

Access to Document

10.1111/pai.14005

Association-in-molecular-profiles-of-ige-sensitization-to-mugwort-pollen-allergens-in-chinese-parents-and-their-offsprin.pdfFinal published version, 1.44 MB

Cite this

Zhao, L., Chen, J., Wang, Y., Guo, Y., Feng, Y., Wang, X., Liu, M., Wang, X., Ma, T., Zhang, H., Chen, X., Zhang, X., Fu, W., Liu, Y., Xu, P., Gao, B., Wang, D., Akkerdaas, J. H., van Ree, R., ... Gao, Z. (2023). Association in molecular profiles of IgE sensitization to mugwort pollen allergens in Chinese parents and their offspring. Pediatric allergy and immunology, 34(8), Article e14005. https://doi.org/10.1111/pai.14005

@article{7bcdb6fc13434aea9f8aef67475fa647,

title = "Association in molecular profiles of IgE sensitization to mugwort pollen allergens in Chinese parents and their offspring",

author = "Lan Zhao and Jiongyi Chen and Yuqi Wang and Yirong Guo and Yan Feng and Xuefeng Wang and Meiling Liu and Xueyan Wang and Tingting Ma and Huanping Zhang and Xiaoxue Chen and Xianqi Zhang and Wanyi Fu and Yi Liu and Puyang Xu and Biyuan Gao and Deyun Wang and Akkerdaas, \{Jaap H.\} and \{van Ree\}, Ronald and Rudolf Valenta and Susanne Vrtala and Zhongshan Gao",

note = "Funding Information: Z. Gao, Y. Liu, and Y. Feng received funds from The Ministry of Science and Technology of China (2019YFE0106600). Y. Guo and L. Zhao received funds from Hangzhou Aileji Biotech Ltd (2016R1 and 2022R1). T. Ma received funds from the Wu jieping Foundation China (320.6750.2022‐02‐29). H. Zhang received funds from the Wu jieping Foundation China (320.6750.2022‐02‐31). Susanne Vrtala received funds from the Austrian government (CN 14/2020). Rudolf Valenta has received research grants from Worg Pharmaceuticals, Hangzhou, China, HVD Biotech, Vienna, Austria, and Viravaxx AG, Vienna, Austria. He serves as a consultant for Viravaxx and Worg. Ronald van Ree reports consultancies for HAL Allergy BV, Citeq BV, Angany Inc., Reacta Healthcare Ltd., Mission MightyMe, and AB Enzymes; speaker's fees from HAL Allergy BV, ALK, and Thermo Fisher Scientific; stock options from Angany Inc. All other authors declare no conflict of interest. Funding Information: This study was carried out with financial support from the National Key R\&D Program of China (2019YFE0106600), OeAD – Austrian Agency for International Cooperation in Education and Research (CN 14/2020), Danube Allergy Research Cluster, Country of Lower Austria, Hangzhou Aileji Biotech Company, Hangzhou, China (Contracts 2016R1and 2022R1) and the Wu jieping Medical Foundation (320.6750.2022-02-29, 320.6750.2022-02-31). Z. Gao, Y. Liu, and Y. Feng received funds from The Ministry of Science and Technology of China (2019YFE0106600). Y. Guo and L. Zhao received funds from Hangzhou Aileji Biotech Ltd (2016R1 and 2022R1). T. Ma received funds from the Wu jieping Foundation China (320.6750.2022-02-29). H. Zhang received funds from the Wu jieping Foundation China (320.6750.2022-02-31). Susanne Vrtala received funds from the Austrian government (CN 14/2020). Rudolf Valenta has received research grants from Worg Pharmaceuticals, Hangzhou, China, HVD Biotech, Vienna, Austria, and Viravaxx AG, Vienna, Austria. He serves as a consultant for Viravaxx and Worg. Ronald van Ree reports consultancies for HAL Allergy BV, Citeq BV, Angany Inc., Reacta Healthcare Ltd., Mission MightyMe, and AB Enzymes; speaker's fees from HAL Allergy BV, ALK, and Thermo Fisher Scientific; stock options from Angany Inc. All other authors declare no conflict of interest. Funding Information: This study was carried out with financial support from the National Key R\&D Program of China (2019YFE0106600), OeAD – Austrian Agency for International Cooperation in Education and Research (CN 14/2020), Danube Allergy Research Cluster, Country of Lower Austria, Hangzhou Aileji Biotech Company, Hangzhou, China (Contracts 2016R1and 2022R1) and the Wu jieping Medical Foundation (320.6750.2022‐02‐29, 320.6750.2022‐02‐31).",

year = "2023",

month = aug,

day = "1",

doi = "10.1111/pai.14005",

language = "English",

volume = "34",

journal = "Pediatric allergy and immunology",

issn = "0905-6157",

publisher = "Blackwell Munksgaard",

number = "8",

}

Zhao, L, Chen, J, Wang, Y, Guo, Y, Feng, Y, Wang, X, Liu, M, Wang, X, Ma, T, Zhang, H, Chen, X, Zhang, X, Fu, W, Liu, Y, Xu, P, Gao, B, Wang, D, Akkerdaas, JH , van Ree, R, Valenta, R, Vrtala, S & Gao, Z 2023, 'Association in molecular profiles of IgE sensitization to mugwort pollen allergens in Chinese parents and their offspring', Pediatric allergy and immunology, vol. 34, no. 8, e14005. https://doi.org/10.1111/pai.14005

TY - JOUR

T1 - Association in molecular profiles of IgE sensitization to mugwort pollen allergens in Chinese parents and their offspring

AU - Zhao, Lan

AU - Chen, Jiongyi

AU - Wang, Yuqi

AU - Guo, Yirong

AU - Feng, Yan

AU - Wang, Xuefeng

AU - Liu, Meiling

AU - Wang, Xueyan

AU - Ma, Tingting

AU - Zhang, Huanping

AU - Chen, Xiaoxue

AU - Zhang, Xianqi

AU - Fu, Wanyi

AU - Liu, Yi

AU - Xu, Puyang

AU - Gao, Biyuan

AU - Wang, Deyun

AU - Akkerdaas, Jaap H.

AU - van Ree, Ronald

AU - Valenta, Rudolf

AU - Vrtala, Susanne

AU - Gao, Zhongshan

N1 - Funding Information: Z. Gao, Y. Liu, and Y. Feng received funds from The Ministry of Science and Technology of China (2019YFE0106600). Y. Guo and L. Zhao received funds from Hangzhou Aileji Biotech Ltd (2016R1 and 2022R1). T. Ma received funds from the Wu jieping Foundation China (320.6750.2022‐02‐29). H. Zhang received funds from the Wu jieping Foundation China (320.6750.2022‐02‐31). Susanne Vrtala received funds from the Austrian government (CN 14/2020). Rudolf Valenta has received research grants from Worg Pharmaceuticals, Hangzhou, China, HVD Biotech, Vienna, Austria, and Viravaxx AG, Vienna, Austria. He serves as a consultant for Viravaxx and Worg. Ronald van Ree reports consultancies for HAL Allergy BV, Citeq BV, Angany Inc., Reacta Healthcare Ltd., Mission MightyMe, and AB Enzymes; speaker's fees from HAL Allergy BV, ALK, and Thermo Fisher Scientific; stock options from Angany Inc. All other authors declare no conflict of interest. Funding Information: This study was carried out with financial support from the National Key R&D Program of China (2019YFE0106600), OeAD – Austrian Agency for International Cooperation in Education and Research (CN 14/2020), Danube Allergy Research Cluster, Country of Lower Austria, Hangzhou Aileji Biotech Company, Hangzhou, China (Contracts 2016R1and 2022R1) and the Wu jieping Medical Foundation (320.6750.2022-02-29, 320.6750.2022-02-31). Z. Gao, Y. Liu, and Y. Feng received funds from The Ministry of Science and Technology of China (2019YFE0106600). Y. Guo and L. Zhao received funds from Hangzhou Aileji Biotech Ltd (2016R1 and 2022R1). T. Ma received funds from the Wu jieping Foundation China (320.6750.2022-02-29). H. Zhang received funds from the Wu jieping Foundation China (320.6750.2022-02-31). Susanne Vrtala received funds from the Austrian government (CN 14/2020). Rudolf Valenta has received research grants from Worg Pharmaceuticals, Hangzhou, China, HVD Biotech, Vienna, Austria, and Viravaxx AG, Vienna, Austria. He serves as a consultant for Viravaxx and Worg. Ronald van Ree reports consultancies for HAL Allergy BV, Citeq BV, Angany Inc., Reacta Healthcare Ltd., Mission MightyMe, and AB Enzymes; speaker's fees from HAL Allergy BV, ALK, and Thermo Fisher Scientific; stock options from Angany Inc. All other authors declare no conflict of interest. Funding Information: This study was carried out with financial support from the National Key R&D Program of China (2019YFE0106600), OeAD – Austrian Agency for International Cooperation in Education and Research (CN 14/2020), Danube Allergy Research Cluster, Country of Lower Austria, Hangzhou Aileji Biotech Company, Hangzhou, China (Contracts 2016R1and 2022R1) and the Wu jieping Medical Foundation (320.6750.2022‐02‐29, 320.6750.2022‐02‐31).

PY - 2023/8/1

Y1 - 2023/8/1

UR - https://www.scopus.com/pages/publications/85167429453

U2 - 10.1111/pai.14005

DO - 10.1111/pai.14005

M3 - Comment/Letter to the editor

C2 - 37622256

SN - 0905-6157

VL - 34

JO - Pediatric allergy and immunology

JF - Pediatric allergy and immunology

IS - 8

M1 - e14005

ER -

Association in molecular profiles of IgE sensitization to mugwort pollen allergens in Chinese parents and their offspring

Access to Document

Other files and links

Cite this